Orchard Therapeutics

NASDAQ: ORTX · Real-Time Price · USD
16.70
0.05 (0.30%)
At close: Jan 23, 2024, 10:00 PM

Orchard Therapeutics Revenue Breakdown

Period Ending Dec 31, 2022 Dec 31, 2021
Collaboration Revenue 2.04M 975K
Collaboration Revenue Growth +109.74% n/a
Product Revenue 20.61M 700K
Product Revenue Growth +2844.29% n/a
Strimvelis Revenue 1.81M n/a
Strimvelis Revenue Growth n/a n/a

Revenue by Geography

Period Ending Dec 31, 2022
France Revenue 3.88M
France Revenue Growth n/a
Germany Revenue 3.05M
Germany Revenue Growth n/a
Italy Revenue 5.54M
Italy Revenue Growth n/a

Operating Expense Breakdown

Period Ending Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selling, General, and Administrative Revenue 11.61M 10.99M 11.13M -27.59M 11.6M 13.73M 13.3M 13.55M 13.04M 14.26M 14.05M 16.23M 12.96M 15.66M 20.14M 18.53M 14.22M 13.67M 10.79M 11.95M 7.47M 7.42M 4.53M
Selling, General, and Administrative Revenue Growth +5.61% -1.28% -140.36% -337.80% -15.49% +3.24% -1.87% +3.93% -8.58% +1.51% -13.40% +25.24% -17.26% -22.27% +8.71% +30.29% +4.01% +26.73% -9.72% +60.09% +0.61% +63.93% n/a
Research and Development Revenue 14.55M 16.7M 15.99M -42.76M 18.1M 21.96M 28.23M 23.35M 20.85M 21.75M 21.04M 22.65M 14.68M 31.57M 24.84M 30.9M 28.49M 40.48M 17.49M 17.43M 27.73M 150.99M 9.17M
Research and Development Revenue Growth -12.83% +4.39% -137.40% -336.19% -17.58% -22.20% +20.94% +11.99% -4.16% +3.40% -7.12% +54.30% -53.50% +27.11% -19.62% +8.44% -29.61% +131.40% +0.38% -37.16% -81.63% +1546.40% n/a
Sales and Marketing Revenue 775K 933K 838K 895K 927K 1.54M 773K 1.59M 1.52M 1.05M 1.1M 2.87M 1.23M 1.84M 2.15M n/a n/a n/a n/a n/a n/a n/a n/a
Sales and Marketing Revenue Growth -16.93% +11.34% -6.37% -3.45% -39.81% +99.22% -51.41% +4.95% +44.52% -4.90% -61.53% +132.71% -33.22% -14.11% n/a n/a n/a n/a n/a n/a n/a n/a n/a